Philip Charles Hoffman to International Agencies
This is a "connection" page, showing publications Philip Charles Hoffman has written about International Agencies.
Connection Strength
0.034
-
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015 Dec 01; 33(34):4007-14.
Score: 0.034